Citi analyst Joanne Wuensch raised the firm’s price target on Johnson & Johnson to $185 from $180 and keeps a Buy rating on the shares post the Q3 report. With the talc litigation settlement proposal moving along, several medical technology acquisitions under its belt, and “level-set 2025 commentary,” Citi reiterates a Buy rating on the shares, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $166 from $163 at Wells Fargo
- Bridgeport jury determines J&J to pay $15M over talc-based powder
- Johnson & Johnson price target raised to $170 from $160 at Stifel
- Legend Biotech weakness a buying opportunity, says Barclays
- Big banks, UnitedHealth report quarterly earnings: Morning Buzz